BidaskClub upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a buy rating to a strong-buy rating in a report issued on Wednesday.
Other research analysts also recently issued reports about the company. Bank of America upped their target price on EXACT Sciences from $58.00 to $67.00 and gave the stock a buy rating in a research note on Wednesday, November 29th. Jefferies Group upped their target price on EXACT Sciences to $60.00 and gave the stock a buy rating in a research note on Tuesday, October 31st. Craig Hallum upped their target price on EXACT Sciences from $46.00 to $61.00 and gave the stock a buy rating in a research note on Tuesday, October 31st. Benchmark reaffirmed a buy rating and set a $60.00 target price (up from $50.00) on shares of EXACT Sciences in a research note on Tuesday, October 31st. Finally, Canaccord Genuity raised EXACT Sciences to a buy rating and set a $60.00 target price for the company in a research note on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $52.84.
EXACT Sciences (NASDAQ EXAS) opened at $45.90 on Wednesday. EXACT Sciences has a twelve month low of $18.30 and a twelve month high of $63.60. The stock has a market capitalization of $5,335.19, a P/E ratio of -39.57 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.
A number of hedge funds and other institutional investors have recently bought and sold shares of EXAS. C M Bidwell & Associates Ltd. acquired a new position in EXACT Sciences in the 4th quarter valued at $117,000. Krilogy Financial LLC raised its stake in EXACT Sciences by 1,460.0% in the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after purchasing an additional 3,650 shares during the last quarter. Crow Point Partners LLC acquired a new position in EXACT Sciences in the 4th quarter valued at $145,000. Oppenheimer Asset Management Inc. raised its stake in EXACT Sciences by 2,925.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 3,072 shares during the last quarter. Finally, Advisory Services Network LLC raised its stake in EXACT Sciences by 6,600.0% in the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock valued at $176,000 after purchasing an additional 3,300 shares during the last quarter. 82.32% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “EXACT Sciences (EXAS) Raised to Strong-Buy at BidaskClub” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://sportsperspectives.com/2018/02/10/exact-sciences-exas-raised-to-strong-buy-at-bidaskclub.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.